Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) AI Stock Analysis

• Market Cap: ₹679.76M
• Dividend Yield: N/A
• Average Volume (3M): 2.25K
• Price to Earnings (P/E): 24.3
• Beta (1Y): 1.23
• Revenue Growth: -31.82%
• EPS Growth: 341.44%
• Country: IN
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.48
• Shares Outstanding: 16,273,800
• 10 Day Avg. Volume: 4,805
• 30 Day Avg. Volume: 2,245
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹46.00
• Price Target Upside: 10.13% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: ₹46.00 ▲(10.13% Upside)

The overall stock score of 52 is primarily influenced by financial performance concerns, particularly in cash flow and revenue decline, and technical indicators suggesting potential bearish momentum. The high P/E ratio further contributes to a cautious outlook. The absence of earnings call data and corporate events means these factors do not influence the score.

Biofil Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.

How the Company Makes Money

Biofil Chemicals & Pharmaceuticals Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include domestic and international sales of its generic and branded medications. Significant factors contributing to its earnings are its extensive distribution network, strategic partnerships with healthcare providers, and its ability to maintain competitive pricing while ensuring high product quality. BIOFILCHEM may also engage in contract manufacturing, providing services to other pharmaceutical companies which further contributes to its revenue.

Biofil Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

Biofil Chemicals & Pharmaceuticals Ltd. demonstrates a mixed financial position. While operational efficiency and a solid balance sheet are present, the recent decline in revenue and cash flow challenges highlight potential areas of concern. A focus on revenue growth and cash flow management is essential for future stability.

Income Statement

Biofil Chemicals & Pharmaceuticals Ltd. has shown fluctuating revenue and profitability over recent years. The gross profit margin has generally remained stable, but net profit margin has seen some volatility. Revenue has decreased in the latest year, indicating potential market challenges. However, the company has managed to maintain positive EBIT and EBITDA margins, suggesting operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a moderate debt-to-equity ratio, indicating manageable leverage. The equity ratio is strong, reflecting a solid capital structure with a reasonable level of shareholder equity. Return on equity has been positive, though showing some variability, highlighting potential for investor returns.

Cash Flow

Cash flow performance has been mixed, with recent periods showing negative free cash flow growth, driven by high capital expenditures relative to generated cash. The operating cash flow to net income ratio indicates some inconsistency in cash generation from operations, suggesting potential liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	402.54M	334.02M	400.35M	300.35M	223.82M	357.50M
Gross Profit	18.57M	20.91M	25.28M	25.63M	28.66M	32.68M
EBITDA	11.81M	11.53M	13.06M	12.65M	14.83M	23.99M
Net Income	6.07M	5.58M	7.09M	5.60M	6.98M	12.41M
Balance Sheet
Total Assets	0.00	509.60M	470.83M	314.06M	187.32M	332.38M
Cash, Cash Equivalents and Short-Term Investments	2.20M	2.55M	22.84M	377.00K	1.45M	4.41M
Total Debt	0.00	4.71M	4.39M	5.22M	4.65M	4.30M
Total Liabilities	-183.97M	321.79M	288.80M	141.04M	18.95M	171.09M
Stockholders Equity	183.97M	187.82M	182.03M	173.01M	168.38M	161.29M
Cash Flow
Free Cash Flow	0.00	-20.24M	23.71M	-1.22M	-2.90M	5.44M
Operating Cash Flow	0.00	-19.24M	23.94M	-1.12M	-2.20M	11.11M
Investing Cash Flow	0.00	-1.00M	-229.00K	-106.00K	-699.00K	-961.00K
Financing Cash Flow	0.00	-45.00K	-1.25M	151.00K	-58.00K	-8.30M

Biofil Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 41.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOFILCHEM, the sentiment is Negative. The current price of 41.77 is below the 20-day moving average (MA) of 43.16, below the 50-day MA of 43.82, and below the 200-day MA of 48.55, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 40.32 is Neutral, neither overbought nor oversold. The STOCH value of 12.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOFILCHEM.

Biofil Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALPHARMA	60 Neutral	₹1.32B	16.10	9.32%	1.45%	-14.16%	10.85%
MANGALAM	58 Neutral	₹1.14B	-11.69	4.51%	―	-16.39%	-410.09%
VAISHALI	55 Neutral	₹1.27B	385.95	1.26%	―	15.13%	-51.89%
INDSWFTLTD	53 Neutral	₹850.39M	0.30	-70.45%	―	2.59%	1891.61%
BIOFILCHEM	52 Neutral	₹679.76M	24.28	―	―	-31.82%	341.44%
LASA	50 Neutral	₹589.69M	-1.78	-17.63%	―	25.82%	-69.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Biofil Chemicals & Pharmaceuticals Ltd. Corporate Events

Biofil Chemicals Appoints New Company Secretary

Biofil Chemicals & Pharmaceuticals Ltd. has announced the appointment of Mr. Apoorv Jain as the new Company Secretary and Compliance Officer, effective April 19, 2025. This change in key managerial personnel is part of the company’s continuous disclosure obligations under SEBI regulations, and it reflects the company’s commitment to maintaining compliance and enhancing its corporate governance framework.

Biofil Chemicals & Pharmaceuticals Ltd. Appoints New Company Secretary

Biofil Chemicals & Pharmaceuticals Ltd. has announced a change in its management team with the appointment of Mr. Apoorv Jain as the new Company Secretary and Compliance Officer. This strategic appointment is expected to enhance the company’s compliance and governance framework, potentially impacting its operational efficiency and stakeholder relations positively.

Biofil Chemicals Appoints New Company Secretary to Enhance Compliance

Biofil Chemicals & Pharmaceuticals Ltd. has announced the appointment of Mr. Apoorv Jain as the new Company Secretary and Compliance Officer, effective April 19, 2025. This strategic move is part of the company’s compliance with SEBI regulations, aimed at enhancing its governance and disclosure practices. The appointment is expected to strengthen the company’s operational management and ensure adherence to regulatory requirements, potentially impacting its market positioning positively.